2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4912 Abaloparatide, a PTHrP analog, promotes stromal niche expansion with altered hematopoietic effects in the murine transgenic NHD13 MDS model

Luojing Chen, PhD, Zhiming Jin, MS2, Zachary Sechrist3, Catherine Caballero, MS4, Nataliia Vdovichenko5, Lizz Lamere6, Ronald Lakony7, Francisco Chaves, PhD8, Adam Tyrlik9, Yumiko Esaki, MD10, Calvin Cole, PhD11, Jane Liesveld, MD12, Laura Calvi, MD13
1 University of Rochester, Rochester, New York, United States
2 University of Rochester, Rochester, New York, United States
3 University of Rochester, Rochester, New York, United States
4 University of Rochester, Rochester, New York, United States
5 University of Rochester, Rochester, New York, United States
6 University of Rochester, Rochester, New York, United States
7 University of Rochester, Rochester, New York, United States
8 University of Rochester, Rochester, New York, United States
9 University of Rochester, Rochester, New York, United States
10 University of Rochester, Rochester, New York, United States
11 University of Rochester, Rochester, New York, United States
12 University of Rochester, Rochester, New York, United States
13 University of Rochester, Rochester, New York, United States

Myelodysplastic Syndromes (MDS) are characterized not only by intrinsic hematopoietic progenitor defects, but also by a severely impaired bone marrow microenvironment (BME). With current MDS therapies offering limited efficacy, targeting the BME has emerged as a potential therapeutic strategy. A major component of the BME are bone marrow stromal cells (BMSCs, mesenchymal stromal cells) that differentiate into osteoblasts and adipocytes and whose dysfunction contributes to MDS pathogenesis. With analysis of large real-world datasets (Blood 144(2024)3798-3799), we found that an increased prevalence of osteoporosis in patients with myeloid malignancies correlates with reduced overall survival. Multiple preclinical studies indicate that MDS-derived BMSCs exhibit impaired osteolineage differentiation. Our studies of parathyroid hormone (PTH) signaling (Nature, 425, 841–846 (2003) showed enhanced BMSC and osteoblast support of hematopoietic stem cells (HSCs), and Abaloparatide (Abalo) treatment increased bone marrow stromal cells in aged mice (J Endocr Soc.2025 22;9)(suppl1). Apart from our early phase studies on Abalo (Blood,140 (suppl),4050-4052), the therapeutic potential of Abalo-an FDA-approved PTHrP analog—remains unexplored in MDS. Here we investigated whether Abalo-mediated stromal niche remodeling can rescue hematopoiesis or alter progenitor dynamics in NHD13 mice.

Methods: 2 to 3-month-old male and female transgenic NHD13 mice (carrying the Vav1 promoter-driven NUP98-HOXD13 fusion oncogene) and age-matched wild-type (WT) controls were treated daily with either Abalo (80 mg/kg BW, S.C.) or vehicle for 4 weeks (n = 11-14 group). Whole-body DXA scans were performed pre- and post-treatment. Femurs and lumbar vertebrae were collected for mCT and histomorphometric analyses. Flow cytometry (FACS) was utilized to quantify bone marrow HSCs, myeloid, lymphoid, and stromal cell populations. In vitro CFU-F and CFU-OB assays were conducted to assess stromal functional capacity. Complete blood counts (CBC) were measured pre- and post-treatment. Data were analyzed using GraphPad Prism 10.2.0, with p < 0.05 considered statistically significant.

Results: Abalo demonstrated potent anabolic effects on bone structure. Compared to vehicle controls, Abalo-treated NHD13 mice exhibited dramatic increases in bone mineral density (BMD), trabecular number, and bone volume fraction (BV/TV) in both femurs (4.2-fold increase, p = 0.008) and lumbar spines (7.9-fold increase, p = 0.028), as confirmed by mCT. In contrast, treated WT mice showed only a 2.4-fold increase in femur BMD and no significant change in the spine. Stromal profiling (FACS) revealed that Abalo expanded key stromal populations in NHD13 mice, including BMSCs (Lin- CD45- CD31-CD51+Sca1+), PαS cells (Lin- CD45- CD31- PDGFR alpha+Sca1+), PαV cells ( Lin- CD45- CD31-CD51+ PDGFR alpha+), and committed osteogenic cells ( Lin- CD45- CD31-CD51+Sca1-). This was functionally validated by significantly elevated CFU-F and CFU-OB colony numbers in vitro. In peripheral blood, Abalo-treated male NHD13 mice exhibited significantly reduced reticulocytes (RET), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and neutrophil percentages, alongside increased lymphocyte percentages and upward trends in RBCs, platelets (PLT), plateletcrit (PCT), and large platelet cell counts (PLCC). Within the hematopoietic compartment, while Abalo expanded LSK, LT-HSC, ST-HSC, and MPP4 populations in WT male mice, these increases were absent in NHD13 mice. Instead, treated NHD13 mice exhibited a significant reduction in megakaryocyte-erythroid progenitors (MEP) and megakaryocyte progenitors (MKP).

Conclusions: Abaloparatide successfully rescues and expands the supportive BMSC and osteogenic niche in NHD13 mice and these effects seem to be more pronounced in male mice. However, this stromal expansion failed to expand early HSCs in this MDS model and led to a significant depletion of downstream megakaryocyte-erythroid progenitors (MEP/MKP). Together with reduced peripheral reticulocytes, microcytosis, and increased platelet production, these findings may suggest that niche remodeling places the dysplastic erythroid/megakaryocyte lineages under high kinetic flux with rapid progenitor consumption toward differentiation, offering key insights into niche-directed stromal therapies for MDS. These findings will need to be corroborated in other murine MDS models and in the human marrow microenvironment.
Luojing Chen, PhD: No relevant conflicts of interest to declare.